Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
6.09
-0.03 (-0.49%)
At close: Apr 28, 2026, 4:00 PM EDT
6.19
+0.10 (1.64%)
After-hours: Apr 28, 2026, 7:41 PM EDT
Xeris Biopharma Holdings Stock Forecast
Stock Price Forecast
The 6 analysts that cover Xeris Biopharma Holdings stock have a consensus rating of "Buy" and an average price target of $10.83, which forecasts a 77.83% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $18.
Price Target: $10.83 (+77.83%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 2, 2026.
Analyst Ratings
The average analyst rating for Xeris Biopharma Holdings stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +64.20% | Mar 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +64.20% | Jan 9, 2026 |
| Barclays | Barclays | Buy Initiates $9 | Buy | Initiates | $9 | +47.78% | Dec 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $18 | Buy | Maintains | $18 | +195.57% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +64.20% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
392.14M
from 291.85M
Increased by 34.37%
Revenue Next Year
481.79M
from 392.14M
Increased by 22.86%
EPS This Year
0.11
from 0.00
Increased by 3,444.08%
EPS Next Year
0.35
from 0.11
Increased by 207.69%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 409.2M | 528.2M | |||||
| Avg | 392.1M | 481.8M | |||||
| Low | 373.6M | 445.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 40.2% | 34.7% | |||||
| Avg | 34.4% | 22.9% | |||||
| Low | 28.0% | 13.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.21 | 0.48 | |
| Avg | 0.11 | 0.35 | |
| Low | 0.05 | 0.17 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 6,448.2% | 325.0% | |
| Avg | 3,444.1% | 207.7% | |
| Low | 1,427.9% | 46.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.